The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Li J, Chen S, Hu Y, Cai J

Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.

Oncology letters. 2016;11(3):2255-2260

Thangam M, Nathan S, Petrovica M, Kar B, Patel M, Loyalka P, Buja LM, Gregoric ID

Procainamide-induced pulmonary fibrosis after orthotopic heart transplantation: a case report and literature review.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2015;24(4):250-3

Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(1):172-80

Santalla Martínez M, Blanco Cid N, Dacal Quintas R

Bortezomib-induced lung toxicity.

Archivos de bronconeumologia. 2014;50(12):564-5

Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, Katoh T, Kusumoto M, Gemma A, Sakai F, Sugiyama Y, Hatake K, Fukuda Y, Kudoh S

Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Cancer science. 2014;105(2):195-201

Yamaguchi T, Sasaki M, Itoh K

Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.

Japanese journal of clinical oncology. 2012;42(7):637-9